Boston Scientific's stock is being evaluated as a potential investment opportunity, with some outlets considering its prospects amid a cardiovascular boom and global growth expansion. However, the stock has fallen to a 2-year low, reportedly due to disappointing trial data, despite a strong quarterly earnings beat. The company's outlook is uncertain, with investors weighing its potential against that of other medtech stocks.